A Study of Combination Therapy in Patients With Resectable Liver Cancer

NCT07684040 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer (Primary and Metastatic)

Interventions

DRUG: Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib

Sponsor

Affiliated Hospital of Guangdong Medical University